<p>Hiroyuki Sasa, president and CEO of Olympus Corp., in December 2013 forecast a return to profit for its camera unit in the next fiscal year. Its Hopkinton-based biotechnology unit did not fare so well, however.</p><p>Olympus Biotech, which is in the process of closing a 60-employee research site in Hopkinton, says it will also shut down a 130-employee manufacturing plant in Lebanon, N.H. by the end of August unless it finds a buyer.</p><p>The firm is the U.S. biotechnology division of Tokyo-based Olympus Corp., which develops and makes medical and surgical products such as gastrointestinal endoscopy, microscopes and digital imaging systems for advanced research as well as cameras and voice recorders. The biotech division was established in December 2010 focused on developing and distributing regenerative medicine products. Its main product is the OP-1 family of collogen implants and putty used to help wounds heal faster.</p><p>On Feb. 28, the company announced that it will close its Hopkinton site. It notified the state's Division of Career Services that the layoffs will begin on March 31, starting with 22 employees to be cut by mid-April. Another 32 positions will be cut in the first two weeks of June, and the remaining cuts will occur between Aug. 29 and Sept. 12. The company said there are no unions representing the employees.</p><p><a href="http://www.bizjournals.com/boston/blog/bioflash/2014/03/olympus-seeks-buyer-for-n-h-wound-healing-product.html">Keep reading...</a></p>